---
title: Comprehensive patient claims data for elevated RWE findings
description: Discover why HealthVerity is the best real-world evidence (RWE) healthcare platform for life sciences research, HEOR, and regulatory-grade insights.
image: https://blog.healthverity.com/hubfs/comprehensive-patient-claims-data-for-elevated-RWE-findings-featured.png
---

Announcing HealthVerity Precision Event Alerts, a next-generation physician alerting solution. [Learn more](https://healthverity.com/news/healthverity-precision-event-alerts-launch/)

- [Contact](https://healthverity.com/contact/)
- [Sign In](https://marketplace.healthverity.com/login/?next=/marketplace/)

[![HealthVerity-Logo-Dark-3](https://blog.healthverity.com/hs-fs/hubfs/HealthVerity-Logo-Dark-3.png?width=1662&height=320&name=HealthVerity-Logo-Dark-3.png)](https://healthverity.com/)

- How We Help 
    - Featured Content 
          - [HealthVerity MarketplaceTM](https://healthverity.com/marketplace/healthverity-marketplace/)
          - [HealthVerity TaxonomySM](https://healthverity.com/taxonomy-portal/)
          - [Life Sciences](https://healthverity.com/life-sciences/)
          - [Identity Manager (HVID)](https://healthverity.com/identity-manager/)
    - Data Ecosystem 
          - [HealthVerity MarketplaceTM](https://healthverity.com/marketplace/healthverity-marketplace/)
          - [HealthVerity TaxonomySM](https://healthverity.com/taxonomy-portal/)
          - [Precision Event Alerts](https://healthverity.com/precision-event-alerts/)
          - [HealthVerity Mastersets](https://healthverity.com/mastersets/portal/)
          - [Media Measurement](https://healthverity.com/media-measurement/)
          - [Insurance Underwriting](https://healthverity.com/insurance-underwriting/)
    - Technology Products 
          - [Identity Manager (HVID)](https://healthverity.com/identity-manager/)
          - [HealthVerity FLOW](https://healthverity.com/flow/portal/)
          - [Governance Manager](https://healthverity.com/governance-manager/)
          - [Smart Contracts](https://healthverity.com/smart-contracts-manager/)
- Symphony 
    - Symphony Health Platform 
          - [Symphony Health Overview](https://healthverity.com/symphony-health/overview/)
          - [Integrated Dataverse](https://healthverity.com/symphony-health/integrated-dataverse-and-source-solutions/)
          - [Symphony HealthCloud](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/)
    - Symphony Solutions 
          - [Health technology and business intelligence solutions](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/)
          - [Integrated Dataverse and Source Solutions](https://healthverity.com/symphony-health/integrated-dataverse-and-source-solutions/)
          - [Brand strategy and sales](https://healthverity.com/symphony-health/optimize-brand-strategy-and-sales-effectiveness/)
          - [HealthRankings](https://healthverity.com/symphony-health/health-rankings/)
          - [Market access](https://healthverity.com/symphony-health/solve-market-access-challenges/)
          - [Patient Journey](https://healthverity.com/symphony-health/understand-the-patient-journey/)
          - [Medicines affordability](https://healthverity.com/symphony-health/making-medicines-more-affordable/)
    - Symphony Products 
          - [PayerSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PayerSource.pdf)
          - [PrescriberSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PrescriberSource.pdf)
          - [PatientSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PatientSource.pdf)
          - [PatientSourceCompleteTM](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PatientSourceComplete.pdf)
          - [PatientSourceDUOTM](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PatientSourceDUO.pdf)
          - [Symphony FLEXTM](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-Symphony-FLEX.pdf)
          - [CustomerSource®](https://healthverity.com/symphony-health/integrated-dataverse-and-source-solutions/)
          - [DiagnosticSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-DiagnosticSource.pdf)
          - [NonRetailSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-NonRetailSource.pdf)
    - Symphony Technology 
          - [Symphony HealthCloud](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/)
          - [Synoma Data Integration](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/)
          - [Vantage Applications](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-Vantage-Applications.pdf)
          - [Metys](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/metys/)
- Who We Serve 
    - [Life Sciences](https://healthverity.com/life-sciences/)
    - [Government](https://healthverity.com/government/)
    - [Insurance](https://healthverity.com/insurance/)
    - [Channel Partners](https://healthverity.com/channel-partners/)
    - [Data Ecosystem Partners](https://healthverity.com/data-ecosystem-partners/)
- Resources 
    - [HealthVerity Blog](https://blog.healthverity.com/)
    - [News & Events](https://healthverity.com/resources/news-and-events/)
    - [Resource Library](https://healthverity.com/resources/resource-library/)
    - [Publications](https://healthverity.com/resources/publications/)
    - [The IPGE Approach](https://healthverity.com/ipge-approach/)
    - [Zombie Data Explained](https://healthverity.com/get-verified/)
- [Careers](https://healthverity.com/careers/)
- [About Us](https://healthverity.com/about-us/)

[Request Demo](https://healthverity.com/request-demo/)

[Open & Closed Claims](https://blog.healthverity.com/tag/open-closed-claims)

# The best closed claims data for RWE and HEOR — HealthVerity taXonomy

[By \- HealthVerity,](https://blog.healthverity.com/author/healthverity)  April 8, 2025

![](https://blog.healthverity.com/hubfs/comprehensive-patient-claims-data-for-elevated-RWE-findings-featured.png)

This is part one of a three-part series (read [part 2](https://blog.healthverity.com/consistent-patient-claims-data-for-elevated-research), [part 3](https://blog.healthverity.com/curated-patient-claims-data-for-research-precision)) on the essential qualities of claims data for life sciences research. Next up: [the role of consistent data in producing reliable and reproducible results](https://blog.healthverity.com/consistent-patient-claims-data-for-elevated-research).

## The best RWE platform for healthcare data: HealthVerity taXonomy

In modern health economics and outcomes research (HEOR), **closed claims data** plays a foundational role in generating reliable, generalizable, and impactful findings. For life sciences teams evaluating the **best real-world evidence (RWE) healthcare platform**, selecting datasets with longitudinal depth and broad **payer diversity** is essential. The ability to track complete patient journeys across multiple payer types enables more accurate real-world insights and regulatory-grade evidence. Without a truly comprehensive [**closed claims dataset**](https://blog.healthverity.com/open-claims-vs-closed-payer-claims), RWE efforts are vulnerable to data gaps, fragmented patient records, and reduced analytical power.

But what defines a comprehensive dataset? And why is comprehensiveness a non-negotiable requirement for closed claims research? This blog explores the necessity of breadth, depth, and payer diversity in claims data **and what distinguishes HealthVerity as the best RWE platform from legacy solutions.**

## Why comprehensive closed claims data matters in life sciences research

### Longitudinal patient journeys enable evidence-based decision-making

A fundamental requirement in HEOR and RWE studies is the ability to consistently follow patients over time. Longitudinal closed claims data allows researchers to assess:

- Disease progression across different treatment lines.
- Long-term medication adherence and real-world efficacy.
- Economic burden shifts due to comorbidities and disease evolution.

A 2023 study from the RAND Corporation found that missing or incomplete longitudinal data introduces bias into patient tracking, cost analysis, and treatment effectiveness evaluations, leading to skewed study outcomes¹. This illustrates that gaps in patient tracking compromise study validity, making longitudinal stability a critical requirement for any closed claims dataset.

Expanding the dataset to reduce data attrition: A dataset that lacks sustained patient follow-up creates severe research limitations. Patients frequently switch insurers, change care settings, or lapse in coverage, causing data attrition. A comprehensive closed claims dataset must include long-term records from commercial, Medicare, and Medicaid sources to prevent breaks in patient histories.

Understanding the real impact of longitudinal data: By leveraging an ever-expanding dataset, researchers can fill the missing gaps in patient journeys, ensuring that RWE studies reflect actual healthcare utilization patterns rather than fragmented snapshots. Studies lacking this comprehensiveness risk misinterpreted efficacy signals, flawed budget impact assessments, and inaccurate economic burden estimates.

### How payer diversity in closed claims data reduces bias in HEOR

A dataset built on a single payer or a limited payer mix is inherently biased. Coverage policies, reimbursement rules, and drug formulary decisions vary widely among payers, meaning that relying on a single-payer dataset can:

- Distort real-world treatment adherence rates.
- Miss critical subpopulations excluded from certain insurance plans.
- Fail to capture the full economic burden across all payer types.

A 2022 report from Medical Economics underscores this issue, stating, *“Real-world data are often fragmented—they include only a sector of healthcare…and incomplete—key outcomes are missing,”* highlighting why multi-payer datasets are essential for representative real-world research².

Avoiding single-payer data pitfalls: Relying solely on commercial insurance data excludes critical populations, such as Medicare patients with chronic diseases and Medicaid patients in vulnerable populations. A truly comprehensive dataset must include a balanced mix of public and private payers to avoid payer-specific distortions.

Capturing market dynamics in real time: Claims datasets that continuously add new payer sources provide an advantage over static datasets locked to a specific period. By ensuring a widening pool of payers, researchers can gain real-time insights into evolving reimbursement patterns, treatment adoption rates, and payer policy changes.

### Why closed claims data is essential for rare disease research

Studying rare diseases is particularly dependent on comprehensive data, as small patient populations require large-scale datasets to reach statistical significance. A 2023 study published in BMJ Public Health confirmed that national insurance claims data are vital in rare disease research, stating:

*\*“The study capitalised on national insurance claims data to gather information on patient characteristics and associated costs to better understand the diagnosis and treatment of rare diseases.”\*³*

Enabling deep research into rare and complex conditions: Rare disease research relies on broad patient representation to ensure sufficient cases for meaningful analysis. Without a comprehensive closed claims dataset, researchers may struggle to:

- Identify eligible patient populations for observational studies.
- Track long-term treatment effects in low-prevalence conditions.
- Conduct comparative effectiveness research (CER) across different care settings.

Supporting faster identification of rare disease populations: By leveraging expansive payer sources, researchers can detect early diagnostic patterns and flag undiagnosed rare disease cohorts. This capability is essential for improving time-to-diagnosis, optimizing trial recruitment, and assessing real-world treatment impact.

 

### HealthVerity taXonomy: The best closed claims data source for life sciences

Without comprehensive [closed claims](https://blog.healthverity.com/open-claims-vs-closed-payer-claims) data, research validity suffers. For HEOR and RWE professionals, longitudinal stability, payer diversity, and continuous expansion are no longer optional, they are the foundation for generating accurate, reproducible, and elevated insights that withstand regulatory, clinical and payer scrutiny.

[HealthVerity taXonomy](https://healthverity.com/taxonomy/) is the only closed claims dataset designed to meet these rigorous standards—**making it a leading choice for pharma teams evaluating real-world evidence healthcare platforms**Built for real-world research, it combines unmatched longitudinal depth with a diverse, balanced, and ever-growing payer ecosystem to deliver a foundation strong enough for today’s most complex evidence generation needs.

Take Alzheimer’s, a disease in which fragmented data has long stalled progress. In taXonomy, researchers can access over 1.3 million Alzheimer’s patients (2016–2024) with:

- **920,000 EMR-linked patients**
- **857,000 with lab results**, including biomarkers likeAPOE status, p-tau and plasma Aβ42/40 ratio
- **830,000 with structured clinical assessments**, includingMMSE, MoCA, PHQ-9
- **110,000 with EMR notes** that capture cognitive testing, behavioral insights, interventions and adverse events
- **Imaging access** supporting real-world safety surveillance for ARIA-E and ARIA-H

Altogether, this represents:

- **71% of Alzheimer’s patients with EMR overlap**
- **66% with lab data**
- **64% with structured clinical assessments**
- **8.5% with deep phenotyping from physician notes**

![taxonomy specifications](https://blog.healthverity.com/hs-fs/hubfs/taxonomy%20specifications.png?width=857&height=359&name=taxonomy%20specifications.png)

This is research-grade, longitudinal, multimodal data, ready for analysis now. In conditions where most datasets offer only fragments, HealthVerity taXonomy delivers context at scale. If you’re ready to pursue research with more power, more precision, and more possibility, start with the only dataset that was built to be truly comprehensive.

(Next in this series: [The critical role of data consistency in HEOR and regulatory-grade research.](https://blog.healthverity.com/consistent-patient-claims-data-for-elevated-research))

<https://bmjpublichealth.bmj.com/content/2/1/e000346>

[![Discover closed claims data with HealthVerity taXonomy ](https://no-cache.hubspot.com/cta/default/5412465/interactive-188589266814.png)](https://blog.healthverity.com/hs/cta/wi/redirect?encryptedPayload=AVxigLIz9JEKwNixn9nAoFtJOv1S222z4bp4YX3XzpofoG%2BNJQWJOyjgEh%2F5YNlufYkjJcV72XCJk04OkWVGjeQXT29s1YII6ChW8lofgLb015oi12LI0icffbuHhW28gp5CNbeP4ZZuVzu8Ifb50w5PvR0JlfqQl1ZfXL%2BbeZs8BPbysfsAQgm%2Br2egSemTas2fBYx%2FhvS%2BM6RfGbMinorf7KO8fbg5pKB0oZLO&webInteractiveContentId=188589266814&portalId=5412465)

# References:

¹ Kranz, A. M., Dworsky, M., Ryan, J., Heins, S. E., & Bhandarkar, M. (2023). State All Payer Claims Databases: Identifying Challenges and Opportunities for Conducting Patient-Centered Outcomes Research and Multi-State Studies. RAND Corporation.  
[https://aspe.hhs.gov/sites/default/files/documents/a2add9e2d2e196f240357fee73cf3990/APCD-PCOR-Report-2023.pdf](https://aspe.hhs.gov/sites/default/files/documents/a2add9e2d2e196f240357fee73cf3990/APCD-PCOR-Report-2023.pdf)

² Brantley, J. (2022). Overcoming Data Fragmentation is Key to Avoiding Future Health Care Crises. Medical Economics.  
[https://www.medicaleconomics.com/view/overcoming-data-fragmentation-is-key-to-avoiding-future-health-care-crises](https://www.medicaleconomics.com/view/overcoming-data-fragmentation-is-key-to-avoiding-future-health-care-crises)

³ Chung, S. C., Toh, S., & Wang, S. V. (2023). Leveraging national insurance claims data for insights on rare diseases: a public health approach. BMJ Public Health, 2(1), e000346.  
[https://bmjpublichealth.bmj.com/content/2/1/e000346](https://bmjpublichealth.bmj.com/content/2/1/e000346)

<https://info.healthverity.com/healthverity-live-april-2025>[![taXonomy closed claims solving for payer coverage scarcity](https://blog.healthverity.com/hs-fs/hubfs/healthverity-live-april-2025-watch-now3.png?width=300&height=390&name=healthverity-live-april-2025-watch-now3.png)](https://healthverity.com/healthverity-taxonomy-2025/)

 

<https://info.healthverity.com/healthverity-live-march-2025>

###### Category

- [Solutions & Best Practices](https://blog.healthverity.com/tag/solutions-best-practices)
- [Trends & Insights](https://blog.healthverity.com/tag/trends-insights)
- [HEOR](https://blog.healthverity.com/tag/heor)
- [Marketplace (RWD)](https://blog.healthverity.com/tag/marketplace-rwd)
- [Thought Leadership](https://blog.healthverity.com/tag/thought-leadership)
- [Industry Updates](https://blog.healthverity.com/tag/industry-updates)
- [Open & Closed Claims](https://blog.healthverity.com/tag/open-closed-claims)
- [Case Studies](https://blog.healthverity.com/tag/case-studies)
- [Commercial Pharma](https://blog.healthverity.com/tag/commercial-pharma)
- [AI](https://blog.healthverity.com/tag/ai)
- [Government](https://blog.healthverity.com/tag/government)
- [eXOs](https://blog.healthverity.com/tag/exos)
- [Audiences](https://blog.healthverity.com/tag/audiences)
- [taXonomy Pathways](https://blog.healthverity.com/tag/taxonomy-pathways)
- [Clinical Notes](https://blog.healthverity.com/tag/clinical-notes)
- [Rare Diseases](https://blog.healthverity.com/tag/rare-diseases)

###### Popular Post

- [The GLP-1 trend: What the real-world data reveals](https://blog.healthverity.com/the-glp-1-surge-what-the-real-world-data-reveals)
- [GLP-1 trends 2025: real-world data, patient outcomes & future therapies](https://blog.healthverity.com/glp-1-trends-2025-real-world-data-patient-outcomes-future-therapies)
- [Open claims vs. closed payer claims: What’s the difference?](https://blog.healthverity.com/open-claims-vs-closed-payer-claims)
- [An integrated approach for deeper insight with both open and closed claims data](https://blog.healthverity.com/an-integrated-approach-for-deeper-insight-with-both-open-and-closed-claims-data)
- [GLP‑1 real‑world data for obesity: A new standard for metabolic care](https://blog.healthverity.com/glp-1-real-world-data-for-obesity-a-new-standard-for-metabolic-care)

###### Subscribe

### Similar Blogs

[![Open claims vs. closed payer claims: What’s the difference?](https://blog.healthverity.com/hs-fs/hubfs/open-claims-vs-closed-payer-claims.png?width=352&name=open-claims-vs-closed-payer-claims.png)](https://blog.healthverity.com/open-claims-vs-closed-payer-claims)

#### [Open claims vs. closed payer claims: What’s the difference?](https://blog.healthverity.com/open-claims-vs-closed-payer-claims)

By [Andrew Goldberg, COO, HealthVerity](https://blog.healthverity.com/author/andrew-goldberg) 22 June 2026

 Open claims and closed payer claims data are essential for understanding the status and activities...

[READ MORE](https://blog.healthverity.com/comprehensive-patient-claims-data-for-elevated-rwe-findings)

[![How AI is changing epidemiology and real-world evidence](https://blog.healthverity.com/hs-fs/hubfs/ask-an-expert-blog-featured-alt-5.png?width=352&name=ask-an-expert-blog-featured-alt-5.png)](https://blog.healthverity.com/how-ai-is-changing-epidemiology-and-real-world-evidence)

#### [How AI is changing epidemiology and real-world evidence](https://blog.healthverity.com/how-ai-is-changing-epidemiology-and-real-world-evidence)

By [Alexa Woodward, Ph.D.](https://blog.healthverity.com/author/alexa-woodward-ph-d) 23 October 2025

 AI changed how we discover medicines. What's next? In just a few years, artificial intelligence...

[READ MORE](https://blog.healthverity.com/comprehensive-patient-claims-data-for-elevated-rwe-findings)

[![Curated data in life sciences: the cornerstone of research readiness and precision](https://blog.healthverity.com/hs-fs/hubfs/curated-patient-claims-data-for-research-precision.png?width=352&name=curated-patient-claims-data-for-research-precision.png)](https://blog.healthverity.com/curated-patient-claims-data-for-research-precision)

#### [Curated data in life sciences: the cornerstone of research readiness and precision](https://blog.healthverity.com/curated-patient-claims-data-for-research-precision)

By [HealthVerity](https://blog.healthverity.com/author/healthverity) 6 May 2025

 This is part three of a three-part series on the essential qualities of claims data for life...

[READ MORE](https://blog.healthverity.com/comprehensive-patient-claims-data-for-elevated-rwe-findings)

#### Who we serve

- [Life Sciences](https://healthverity.com/life-sciences/)
- [Government](https://healthverity.com/government/)
- [Insurance](https://healthverity.com/insurance/)
- [Channel Partners](https://healthverity.com/channel-partners/)
- [Data Ecosystem Partners](https://healthverity.com/data-ecosystem-partners/)

#### How we help

- [HealthVerity Marketplace](https://healthverity.com/marketplace/)
- [HealthVerity Mastersets](https://healthverity.com/mastersets/)
- [HealthVerity FLOW](https://healthverity.com/flow/)
- [The IPGE Approach](https://healthverity.com/ipge-approach/)

#### Resources

- [HealthVerity Blog](https://blog.healthverity.com/)
- [News & Events](https://healthverity.com/resources/news-and-events/)
- [Resource Library](https://healthverity.com/resources/resource-library/)
- [Publications](https://healthverity.com/resources/publications/)

#### Our company

- [About Us](https://healthverity.com/about-us/)
- [Leadership](https://healthverity.com/about-us/#leadership)
- [Board of Directors](https://healthverity.com/about-us/#board)
- [Careers](https://healthverity.com/careers/)
- [Contact](https://healthverity.com/contact/)

©2026 HealthVerity, Inc.    |    [Terms & Conditions](https://healthverity.com/terms-and-conditions/)    |    [Privacy Policy](https://healthverity.com/privacy-policy/)

<https://twitter.com/healthverity> <https://www.linkedin.com/company/healthverity>

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "articleSection" : "Data Insights",
  "author" : {
    "@type" : "Organization",
    "name" : "HealthVerity"
  },
  "dateModified" : "2025-08-12",
  "datePublished" : "2023-10-19",
  "description" : "Discover how comprehensive, multi-payer closed claims data from HealthVerity taXonomy delivers longitudinal depth, diversity, and completeness for high-quality real-world evidence (RWE) and HEOR studies.",
  "headline" : "Comprehensive Patient Claims Data for Elevated RWE Findings",
  "keywords" : [ "comprehensive claims data", "closed payer claims", "multi-payer data", "real-world data", "RWD", "RWE", "HEOR", "longitudinal data", "HealthVerity taXonomy" ],
  "mainEntityOfPage" : {
    "@id" : "https://blog.healthverity.com/comprehensive-patient-claims-data-for-elevated-rwe-findings",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://blog.healthverity.com/hubfs/healthverity-logo.png"
    },
    "name" : "HealthVerity"
  },
  "url" : "https://blog.healthverity.com/comprehensive-patient-claims-data-for-elevated-rwe-findings"
}
```

```json
{
  "@context" : "https://schema.org",
  "@type" : "FAQPage",
  "mainEntity" : [ {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "HealthVerity taXonomy aggregates closed payer claims from a broad mix of payers, ensuring diverse, longitudinal, and representative datasets that minimize bias and improve RWE validity."
    },
    "name" : "What makes HealthVerity claims data comprehensive?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Payer diversity reduces the risk of over-representing certain populations, making insights more generalizable across different demographics and geographies."
    },
    "name" : "Why is payer diversity important?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "RWE, HEOR, epidemiology, rare disease studies, and market access initiatives all benefit from the breadth and depth of comprehensive claims data."
    },
    "name" : "What types of research benefit from comprehensive claims data?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Through rigorous data ingestion, normalization, and identity resolution processes, HealthVerity ensures claims data is complete, standardized, and ready for analysis."
    },
    "name" : "How does HealthVerity ensure data quality?"
  } ]
}
```

```json
{
  "@context" : "https://schema.org",
  "@type" : "BreadcrumbList",
  "itemListElement" : [ {
    "@type" : "ListItem",
    "item" : "https://www.healthverity.com/",
    "name" : "Home",
    "position" : 1
  }, {
    "@type" : "ListItem",
    "item" : "https://blog.healthverity.com/",
    "name" : "Blog",
    "position" : 2
  }, {
    "@type" : "ListItem",
    "item" : "https://blog.healthverity.com/comprehensive-patient-claims-data-for-elevated-rwe-findings",
    "name" : "Comprehensive Patient Claims Data for Elevated RWE Findings",
    "position" : 3
  } ]
}
```